2,264 press releases in English indexed under biotech & pharma.
NEW YORK, Sept. 22, 2026 -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
MEXICO CITY, Sept. 22, 2026 -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that the Company filed a...
Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -- XENE shares fell as much as 27.6%. NEW YORK, Sept. 22, 2026 -- A roughly...
HOUSTON, Sept. 22, 2026 -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Company's warrant inducement transaction. The original press release incorrectly stated that...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -...
TORONTO, Sept. 22, 2026 -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.
As per SNS Insider, the Global Metal-Organic Framework (MOF) Market is projected to reach USD 4.71 billion by 2035 as clean energy, gas separation, catalysis and pharmaceutical applications expand adoption of advanced porous materials As per SNS Insider, the Global Metal-Organic Framework (MOF) Market is projected to reach USD 4.71 billion by 2035 as clean energy, gas separation, catalysis and pharmaceutical applications expand adoption of advanced porous materials
In the news release, Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding, issued 22-Sep-2026 by Decoy Therapeutics, Inc over PR Newswire, we are advised by the company that the original version contained incorrect information introduced...
A securities class action alleges Unicycive Therapeutics told investors its third-party manufacturer had made "significant progress" toward regaining FDA compliance, while the Company had never verified that claim through its own inspection of the facility A securities class action alleges Unicycive Therapeutics told investors its third-party manufacturer had made "significant progress" toward regaining FDA compliance, while the Company had never verified that claim through its own inspection of the facility
Dublin, Sept. 22, 2026 -- "Drug Discovery Informatics Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
Press release – No. 17 / 2026
Ashburn, Virginia, September 22nd, 2026, FinanceWire – First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need – Follows July 2026 FDA Clearance of the … Continue reading "Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome"